Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Oxcarbazepine].

S Arroyo1

  • 1Unidad de Epilepsia, Hospital Clínico, Barcelona.

Neurologia (Barcelona, Spain)
|December 12, 2001
PubMed
Summary
This summary is machine-generated.

Oxcarbazepine (OXC) is an effective antiepileptic drug for partial seizures, offering comparable efficacy to other treatments with improved tolerability. It presents a favorable safety profile, with most adverse events being mild and transient.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Thoracic insufficiency syndrome].

Acta ortopedica mexicana·2021
Same author

Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study.

Acta neurologica Scandinavica·2010
Same author

Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.

Human mutation·2008
Same author

[Interdigital erythrasma: clinical, epidemiologic, and microbiologic findings].

Actas dermo-sifiliograficas·2008
Same author

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.

Neurology·2008
Same author

[A pilot study on a specific measure for sleep disorders in Parkinson's disease: SCOPA-Sleep].

Revista de neurologia·2006
Same journal

[Amyotrophic neuralgia secondary to Vaxzevria (AstraZeneca) COVID-19 vaccine].

Neurologia (Barcelona, Spain)·2024
Same journal

[SARS-CoV-2 infection: Possible underdiagnosis of cerebral venous sinus thrombosis].

Neurologia (Barcelona, Spain)·2024
Same journal

[Bell's palsy following COVID-19 vaccination: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Parsonage-Turner syndrome post-infection by SARS-CoV-2: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Acute transverse myelitis following SARS-CoV-2 infection].

Neurologia (Barcelona, Spain)·2024
Same journal

[Neurological complications in critical patients with COVID-19].

Neurologia (Barcelona, Spain)·2024
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Therapeutics

Background:

  • Oxcarbazepine (OXC) is a derivative of carbamazepine (CBZ), developed as a novel antiepileptic drug.
  • OXC exhibits high bioavailability and is approximately 40% protein-bound.
  • Its metabolic pathway differs from CBZ, producing a monohydroxy derivative (MHD) responsible for its efficacy, notably lacking an epoxy metabolite.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Oxcarbazepine (OXC) in treating partial and secondarily generalized seizures.
  • To compare the safety profile of OXC with established antiepileptic drugs such as carbamazepine (CBZ), valproic acid, and phenytoin.

Main Methods:

  • Review of several clinical trials investigating OXC as both add-on therapy and monotherapy for partial seizures.

Related Experiment Videos

  • Analysis of adverse event data, focusing on frequency, severity, and management of side effects.
  • Assessment of pharmacokinetic and metabolic profiles of OXC.

    • Main Results:

    • Oxcarbazepine (OXC) demonstrated significant efficacy in partial seizures, comparable to carbamazepine (CBZ), valproic acid, and phenytoin.
    • OXC was associated with fewer adverse events and better tolerability compared to the comparator drugs.
    • Common adverse events included sedation, somnolence, headache, dizziness, and nausea, which were generally transient and manageable with dose adjustments. Severe hematological, renal, or hepatic events were not observed.
    • Asymptomatic hyponatremia was noted, particularly in predisposed patients.

    Conclusions:

    • Oxcarbazepine (OXC) is a well-tolerated and effective antiepileptic medication for partial seizures in adults and children.
    • Its distinct metabolic profile and favorable safety, including reduced adverse events compared to older drugs, make it a valuable therapeutic option.
    • While generally safe, monitoring for asymptomatic hyponatremia is recommended.